Follow our progress

New subgroup analysis supports ensifentrine’s efficacy in symptomatic COPD patients LONDON and RALEIGH, N.C., Aug. 24, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that

Results expected in the first half of 2021 LONDON and RALEIGH, N.C., Aug. 19, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of the second, multiple dose,

Completed $200 million private placement post period Phase 3 COPD clinical trials planned to start later this year Pilot clinical study in patients hospitalized with COVID-19 planned to start in the third quarter Conference Call Today at 9:00 am EDT / 2:00 pm BST LONDON and RALEIGH, N.C., Aug.

LONDON and RALEIGH, N.C., Aug. 07, 2020 (GLOBE NEWSWIRE) — NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :

LONDON and RALEIGH, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, notifies the following transactions by persons discharging managerial

LONDON and RALEIGH, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, and Mark Hahn, Chief

LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) — NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :

LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,  announces that it will report its audited financial results for the three and six months ended June

LONDON and RALEIGH, N.C., July 27, 2020 (GLOBE NEWSWIRE) — NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :